EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc.(OTCQB:"BIEI") a biotech research company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer, as well as for neurofibromatosis, atherosclerosis and muscular dystrophy, announced the filing of a provisional patent on a second drug to treat fibromyalgia, neuropathic pain, MS symptoms, and alcohol and chemical addiction. This new drug is in addition to Premier’s existing Feldetrex® drug, to compete in this segment of the health care market representing an opportunity of $16B annually.
William A. Hartman, President and CEO of Premier Biomedical stated, “We are continuing to advance our technology to improve and expand our healthcare products to help relieve the pain and suffering of patients afflicted with these diseases and conditions, not only here in the U.S., but also in Brazil, Asia and Europe through pending and future joint ventures.”
Contact William Hartman at (724) 633-7033, PR@premierbiomedical.com.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB:BIEI) is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via license agreements, the technology behind multiple provisional patents in the United States and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center. The company's R&D efforts are centered in El Paso, TX. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI".
For more information, visit our website http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
